Abiopharma

FDA approve PAZOPANIB HYDROCHLORIDE

Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025

IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer

Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025

Burning Rock Reports Second Quarter 2025 Financial Results

Alcon - Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025

Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

Alterity Therapeutics Raises A$20.0 million in Strategic Placement

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis

CAPR截止日期：Rosen Law Firm敦促遭受損失的Capricor Therapeutics, Inc. (NASDAQ: CAPR)股東與法律事務所聯絡以瞭解有關其權利的資訊

CAPR截止日期：Rosen Law Firm敦促蒙受损失的Capricor Therapeutics, Inc. (NASDAQ: CAPR) 股东与律所联系以了解有关其权利的信息

Best Cheap Electric Cars for Budget-Conscious Drivers in 2025

How to Change Your Passcode on iPhone